Rare diseases
Investigational molecules
Locations
Clinical trials in Poland – page 2232 699 clinical trials in Poland across 203 research sites in 238 cities. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in PolandBadaniaKliniczne.pl(opens in a new tab)PolandPolandPolandPolandPolandPolandPolandPolandPolandPolandPolandPolandWhere most of the country's trials are run
Shares are of these cities' trials together.
238 cities, A–Z – pick yours to filter the trials
What the registry says about research in the country
Clinical research in Poland encompasses extensive studies in oncology, focusing on a wide range of solid tumors and hematologic malignancies. Trials investigate novel immunotherapies, targeted therapies, and combination treatment regimens for conditions including non-small cell lung cancer, breast cancer, melanoma, and various forms of lymphoma. Research efforts emphasize improving survival outcomes and quality of life through innovative therapeutic approaches, particularly in metastatic disease and treatment-resistant cases.
Studies evaluate both monotherapy and combination approaches, including checkpoint inhibitors, antibody-drug conjugates, and CAR-T cell therapies, with particular attention to biomarker-driven patient selection and personalized treatment strategies.
Poland participates in numerous trials addressing autoimmune conditions and chronic inflammatory diseases. Research focuses on rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and inflammatory bowel diseases including Crohn's disease and ulcerative colitis. These studies evaluate novel biologic agents, JAK inhibitors, and emerging therapeutic targets aimed at achieving disease remission and preventing structural damage.
Trials investigate the efficacy of monoclonal antibodies, small molecule inhibitors, and immunomodulatory therapies in achieving clinical remission, mucosal healing, and sustained disease control while minimizing corticosteroid use.
Cardiovascular research in Poland addresses heart failure, acute coronary syndromes, atherosclerotic cardiovascular disease, and hypertrophic cardiomyopathy. Clinical trials evaluate interventions to reduce cardiovascular events, improve cardiac function, and manage complications such as atrial fibrillation and pulmonary hypertension. Studies focus on both acute management and long-term disease modification.
Research evaluates SGLT2 inhibitors, cardiac myosin inhibitors, anti-inflammatory agents, and lipid-lowering therapies to improve outcomes, reduce hospitalizations, and enhance exercise capacity in patients with various cardiovascular conditions.
Polish clinical research addresses multiple sclerosis, Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions. Trials investigate disease-modifying therapies, symptomatic treatments, and neuroprotective strategies for conditions including amyotrophic lateral sclerosis, Huntington's disease, and myasthenia gravis. Studies emphasize slowing disease progression and improving functional outcomes.
Research evaluates monoclonal antibodies, immunomodulatory therapies, complement inhibitors, and novel mechanisms targeting neuroinflammation and protein aggregation to modify disease course and preserve neurological function.
Clinical trials in Poland investigate treatments for chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension. Research focuses on improving lung function, reducing exacerbations, and managing progressive fibrosing interstitial lung diseases. Studies evaluate both maintenance therapies and interventions for acute exacerbations.
Trials assess biologic therapies, bronchodilators, anti-fibrotic agents, and pulmonary vasodilators to improve respiratory function, exercise capacity, and quality of life in patients with chronic respiratory conditions.
Poland conducts research on atopic dermatitis, psoriasis, hidradenitis suppurativa, and other chronic inflammatory skin diseases. Clinical trials evaluate systemic and topical therapies aimed at achieving clear or almost clear skin, reducing pruritus, and improving quality of life. Studies focus on moderate to severe disease requiring systemic intervention.
Research evaluates JAK inhibitors, IL-17 inhibitors, IL-23 inhibitors, and other targeted biologic therapies to achieve sustained disease control and improve skin clearance in patients with treatment-resistant dermatologic conditions.
Clinical research addresses type 2 diabetes, obesity, dyslipidemia, and metabolic dysfunction-associated steatohepatitis. Trials investigate interventions to improve glycemic control, promote weight loss, reduce cardiovascular risk, and prevent progression of liver fibrosis. Studies also address growth hormone deficiency and other endocrine conditions.
Trials evaluate GLP-1 receptor agonists, SGLT2 inhibitors, dual and triple agonists, and novel agents targeting metabolic pathways to improve cardiometabolic outcomes and reduce disease complications.
Poland participates in studies addressing chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis, and lupus nephritis. Research focuses on slowing progression of kidney disease, reducing proteinuria, and preventing end-stage renal disease. Trials also investigate treatments for urothelial carcinoma and bladder cancer.
Studies evaluate complement inhibitors, immunosuppressive therapies, SGLT2 inhibitors, and mineralocorticoid receptor antagonists to preserve renal function and improve outcomes in patients with progressive kidney disease.
Clinical trials in Poland address rare genetic disorders including Duchenne muscular dystrophy, spinal muscular atrophy, hemophilia, Fabry disease, and various lysosomal storage disorders. Research focuses on gene therapies, enzyme replacement, and disease-modifying treatments aimed at improving functional outcomes and quality of life.
Studies investigate gene therapy, antisense oligonucleotides, enzyme replacement therapy, and substrate reduction therapy to address underlying disease mechanisms and improve patient outcomes in rare conditions.
Research in Poland addresses major depressive disorder, schizophrenia, bipolar disorder, and treatment-resistant depression. Clinical trials evaluate novel antidepressants, antipsychotics, and adjunctive therapies aimed at improving symptom control and functional outcomes. Studies also address agitation in Alzheimer's disease and psychosis associated with dementia.
Trials investigate novel receptor modulators, rapid-acting antidepressants, and adjunctive therapies targeting different neurotransmitter systems to improve treatment outcomes in patients with psychiatric disorders.
Clinical research addresses age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and geographic atrophy. Trials evaluate anti-VEGF therapies, complement inhibitors, and novel agents aimed at preserving vision and preventing disease progression. Studies focus on both neovascular and atrophic forms of retinal disease.
Research evaluates intravitreal injections, sustained-release formulations, and gene therapies to improve visual acuity and reduce treatment burden in patients with chronic retinal conditions.
Poland participates in trials for infectious disease prevention and treatment, including studies on COVID-19, respiratory syncytial virus, influenza, and bacterial infections. Research includes vaccine development, immunization strategies, and treatments for complicated infections and antimicrobial resistance.
Studies evaluate novel vaccines, monoclonal antibodies, and antimicrobial agents to prevent and treat infectious diseases, with emphasis on vulnerable populations and emerging resistance patterns.
Clinical research in Poland addresses pediatric populations across multiple therapeutic areas including juvenile idiopathic arthritis, pediatric asthma, growth disorders, and rare genetic diseases. Trials evaluate age-appropriate formulations and dosing regimens for conditions requiring long-term management. Studies emphasize safety and developmental considerations in children and adolescents.
Research evaluates biologic therapies, growth hormone preparations, and immunomodulatory agents specifically developed or adapted for pediatric use, focusing on efficacy, safety, and impact on growth and development.
Poland conducts studies on myelodysplastic syndromes, myelofibrosis, immune thrombocytopenia, and paroxysmal nocturnal hemoglobinuria. Clinical trials investigate disease-modifying therapies, supportive care interventions, and treatments targeting underlying disease mechanisms. Research addresses both primary hematologic conditions and complications of bone marrow disorders.
Trials evaluate JAK inhibitors, complement inhibitors, thrombopoietin receptor agonists, and hypomethylating agents to improve blood counts, reduce symptoms, and modify disease progression in patients with hematologic disorders.
Research addresses chronic pain conditions including osteoarthritis, neuropathic pain, and chronic low back pain. Clinical trials evaluate analgesic therapies, anti-inflammatory agents, and interventions targeting pain mechanisms. Studies also address musculoskeletal disorders such as rotator cuff tendinopathy and spasticity.
Trials investigate NSAIDs, opioid and non-opioid analgesics, nerve growth factor inhibitors, and botulinum toxin to provide effective pain relief and improve function in patients with chronic pain conditions.
Clinical research addresses liver diseases including primary biliary cholangitis, primary sclerosing cholangitis, and alcohol-related liver disease. Studies also investigate eosinophilic esophagitis, gastroparesis, and other gastrointestinal motility disorders. Research focuses on preventing disease progression and managing complications.
Trials evaluate nuclear receptor agonists, anti-fibrotic agents, prokinetic agents, and immunomodulatory therapies to improve liver function, reduce inflammation, and manage symptoms in patients with chronic gastrointestinal and hepatic conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
